What is the half-life of Kenalog (triamcinolone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Kenalog (Triamcinolone Acetonide) Half-Life

The terminal elimination half-life of triamcinolone acetonide (Kenalog) is approximately 213 hours (about 9 days) following intra-articular injection, though the duration of clinical effect and cortisol suppression is typically shorter at 4-6 days. 1

Pharmacokinetic Profile

The half-life of triamcinolone acetonide varies significantly based on the route of administration and formulation:

  • Intra-articular/Intralesional injections: The most robust pharmacokinetic data shows a terminal elimination half-life of 213 hours (approximately 8.9 days) in a noncompartmental analysis following fluoroscopically guided lumbar facet joint injections 1

  • Peak serum concentrations: Following intra-articular injection, peak median triamcinolone concentration of 3.6 ng/mL occurs within 24 hours 1

  • Duration of clinical effect: When administered intravitreally at approximately 20mg to non-vitrectomized eyes, the duration of therapeutic effect and side-effects extends 6-9 months 2

Clinical Implications of Prolonged Half-Life

Endocrine Suppression

Serum cortisol levels remain suppressed (<30 ng/mL) for an average of 4.4 days following injection, despite the much longer drug half-life. 1 The maximum cortisol suppression occurs when triamcinolone serum levels exceed 1.9 ng/mL 1

Therapeutic Duration

  • Intralesional use for acne: Triamcinolone acetonide flattens most acne nodules within 48-72 hours 3
  • Intravitreal use: Single injection effects last 6-9 months depending on dosage 2
  • Repeated injections: Can suppress the hypothalamic-pituitary-adrenal axis with chronic use 3

Important Clinical Caveats

The prolonged half-life of triamcinolone significantly increases the risk for serious drug-drug interactions, particularly in patients taking medications that inhibit corticosteroid metabolism. 1 This extended pharmacokinetic profile means:

  • Adverse effects may persist for weeks after administration 1
  • Systemic absorption occurs even with local injection routes 1
  • Monitoring for steroid-related complications should extend well beyond the injection date 3

The discrepancy between the 213-hour elimination half-life and the shorter 4.4-day cortisol suppression period suggests that clinically relevant systemic effects resolve before complete drug elimination 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.